 Bristol Myers Squibb Co NYSE: BMY and Nektar Therapeutics NASDAQ: NKTR have an update following the first analysis of the Phase 3 PIVOT IO-001 study of bempegaldesleukin combined with Opdivo nivolumab in previously untreated unresectable or metastatic melanoma. 